These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17960354)

  • 1. [Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].
    Voss B; Thienel R; Leucht S; Kircher T
    Nervenarzt; 2008 Jan; 79(1):47-8, 50-2, 54-9. PubMed ID: 17960354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
    Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
    Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylcholinesterase inhibitors for schizophrenia.
    Singh J; Kour K; Jayaram MB
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD007967. PubMed ID: 22258978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
    Sharma T; Reed C; Aasen I; Kumari V
    Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.
    Ritchie CW; Ames D; Clayton T; Lai R
    Am J Geriatr Psychiatry; 2004; 12(4):358-69. PubMed ID: 15249273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.
    Ferreri F; Agbokou C; Gauthier S
    J Psychiatry Neurosci; 2006 Nov; 31(6):369-76. PubMed ID: 17136214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.
    Whyte EM; Lenze EJ; Butters M; Skidmore E; Koenig K; Dew MA; Penrod L; Mulsant BH; Pollock BG; Cabacungan L; Reynolds CF; Munin MC
    Cerebrovasc Dis; 2008; 26(3):317-21. PubMed ID: 18667813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review.
    Repantis D; Laisney O; Heuser I
    Pharmacol Res; 2010 Jun; 61(6):473-81. PubMed ID: 20193764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?
    Isik AT; Bozoglu E; Yay A; Soysal P; Ateskan U
    Am J Alzheimers Dis Other Demen; 2012 May; 27(3):171-4. PubMed ID: 22573283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.
    Ribeiz SR; Bassitt DP; Arrais JA; Avila R; Steffens DC; Bottino CM
    CNS Drugs; 2010 Apr; 24(4):303-17. PubMed ID: 20297855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
    Kaduszkiewicz H; Zimmermann T; Beck-Bornholdt HP; van den Bussche H
    BMJ; 2005 Aug; 331(7512):321-7. PubMed ID: 16081444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration.
    Kurz A; Van Baelen B
    Dement Geriatr Cogn Disord; 2004; 18(2):217-26. PubMed ID: 15237280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.